1. Home
  2. BATRA vs ACAD Comparison

BATRA vs ACAD Comparison

Compare BATRA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series A

BATRA

Atlanta Braves Holdings Inc. Series A

HOLD

Current Price

$43.37

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.04

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATRA
ACAD
Founded
1991
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
4.6B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
BATRA
ACAD
Price
$43.37
$27.04
Analyst Decision
Strong Buy
Buy
Analyst Count
3
22
Target Price
$58.00
$29.05
AVG Volume (30 Days)
54.4K
1.4M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.53
EPS
N/A
1.54
Revenue
$723,307,000.00
$1,047,118,000.00
Revenue This Year
$12.40
$15.16
Revenue Next Year
$6.78
$11.42
P/E Ratio
N/A
$17.62
Revenue Growth
6.62
12.69
52 Week Low
$38.67
$13.40
52 Week High
$50.50
$27.73

Technical Indicators

Market Signals
Indicator
BATRA
ACAD
Relative Strength Index (RSI) 59.51 69.78
Support Level $42.06 $26.38
Resistance Level $42.85 $27.73
Average True Range (ATR) 0.64 0.83
MACD 0.13 0.14
Stochastic Oscillator 82.73 88.00

Price Performance

Historical Comparison
BATRA
ACAD

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: